AR066171A1 - Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer. - Google Patents
Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer.Info
- Publication number
- AR066171A1 AR066171A1 ARP080104193A ARP080104193A AR066171A1 AR 066171 A1 AR066171 A1 AR 066171A1 AR P080104193 A ARP080104193 A AR P080104193A AR P080104193 A ARP080104193 A AR P080104193A AR 066171 A1 AR066171 A1 AR 066171A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- atom
- hydrogen atom
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicacion 1: Compuesto de formula (1) en la que: A representa un grupo -NR1R'1 o alcoxi C1-6; Z y Z' representan respectivamente N y CH; N y CF; N y N ; CH y CH; CH y N; L representa un grupo -CH=CH- o -CH2CH2- o -(CH2)n-Y- en el que el grupo Y (unido al C=O) representa un átomo de oxigeno o un grupo -NH- y n es un numero entero que va de 1 a 4; R1 y R'1 son tal que: (i) R1 representa: un átomo de hidrogeno; un grupo arilo eventualmente sustituido por uno o varios átomos de halogeno; un grupo heteroarilo; un grupo cicloalquilo C3-6; un grupo alquilo C1-6, eventualmente sustituido por uno o varios grupos hidroxi o alcoxi C1-6, preferentemente alcoxi C1-4; un grupo arilo; un grupo cicloalquilo C3-6; un grupo heteroarilo, un grupo heterocicloalquilo; un grupo -NRaRb en el que Ra y Rb representan independientemente uno de otro un átomo de hidrogeno o un grupo alquilo C1-6, preferentemente alquilo C1-4 o forman junto con el átomo de nitrogeno al que están unidos un grupo heterocicloalquilo que comprende eventualmente otro átomo de nitrogeno y R1' representa un átomo de hidrogeno o un grupo alquilo C1-6 o (ii) R1 y R'1 forman junto con el átomo de nitrogeno al que están unidos un grupo heterocicloalquilo; R2 representa un grupo -Q-R4; Q representa un átomo de oxígeno o el grupo -NH-; R4 representa un átomo de hidrogeno, un grupo heteroarilo, un grupo cicloalquilo C3-6, un grupo alquilo C1-6, eventualmente sustituido por: uno o varios grupos hidroxi o alcoxi C1-6, preferentemente alcoxi C1-4; un grupo heteroarilo, un grupo heterocicloalquilo; un grupo -NRcRd en el que Rc y Rd representan independientemente uno del otro un átomo de hidrogeno o un grupo alquilo C1-6 o forman junto con el átomo de nitrogeno al que están unidos un grupo heterocicloalquilo que comprende eventualmente en el ciclo otro heteroátomo tal como un átomo de nitrogeno, de oxigeno o el grupo -S(O)q con q= 0, 1 o 2 y estando eventualmente sustituido con uno o varios sustituyente(s), idénticos o diferentes los unos de los otros cuando hay varios, elegido(s) entre un átomo de halogeno o un grupo -OH; alcoxi C1-4 o alquilo C1-4; R3 representa al menos un sustituyente del nucleo piridino elegido entre un átomo de hidrogeno o de fluor, un grupo alquilo C1-4, alcoxi C1-4, -OH, -CN o -NReRf en el que Re y Rf representan un átomo de hidrogeno o un grupo alquilo C1-4 o bien Re representa un átomo de hidrogeno y Rf representa un grupo alquilo C1-4, -C(=O)-Oalquilo C1-4 o -C(=O)-alquilo C1-4. Reivindicacion 37: Compuesto de formula (2) en la que L representa un grupo -CH=CH- o -CH2CH2 o -(CH2)n-Y-, en el que el grupo Y (unido al C=O) representa un átomo de oxígeno o un grupo -NH- y n es un numero entero que va de 1 a 4, R3 es tal como se define en la reivindicacion 1, 2 o 27 y K y K' representan un átomo de hidrogeno, un grupo alquilo o arilo, opcionalmente unidos entre ellos para formar juntos con el átomo de boro y los dos átomos de oxigeno un ciclo de 5 a 7 eslabones. Reivindicacion 38: Compuesto segun la reivindicacion 37, caracterizado por que -B(OK)(OK') representa uno de los grupos siguientes de formulas (3).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0706799A FR2921657A1 (fr) | 2007-09-28 | 2007-09-28 | Derives de nicotinamide, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066171A1 true AR066171A1 (es) | 2009-07-29 |
Family
ID=39356668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104193A AR066171A1 (es) | 2007-09-28 | 2008-09-26 | Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20100222319A1 (es) |
| EP (1) | EP2205566A2 (es) |
| JP (1) | JP2010540504A (es) |
| KR (1) | KR20100065165A (es) |
| CN (1) | CN101808996A (es) |
| AR (1) | AR066171A1 (es) |
| AU (1) | AU2008334457A1 (es) |
| BR (1) | BRPI0817973A2 (es) |
| CA (1) | CA2700559A1 (es) |
| CL (1) | CL2008002893A1 (es) |
| FR (1) | FR2921657A1 (es) |
| IL (1) | IL204663A0 (es) |
| MX (1) | MX2010003445A (es) |
| PA (1) | PA8797301A1 (es) |
| PE (1) | PE20091033A1 (es) |
| RU (1) | RU2010116765A (es) |
| TW (1) | TW200918056A (es) |
| UY (1) | UY31367A1 (es) |
| WO (1) | WO2009074749A2 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2439736T3 (es) | 2005-11-08 | 2014-01-24 | Vertex Pharmaceuticals Incorporated | Moduladores heterocíclicos de transportadores de casete de unión a ATP |
| CN104447716A (zh) | 2007-05-09 | 2015-03-25 | 沃泰克斯药物股份有限公司 | Cftr调节剂 |
| CN101910156B (zh) | 2007-12-07 | 2013-12-04 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
| CA2989620C (en) | 2007-12-07 | 2022-05-03 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| EP2271622B1 (en) | 2008-02-28 | 2017-10-04 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as CFTR Modulators |
| FR2943669B1 (fr) * | 2009-03-24 | 2011-05-06 | Sanofi Aventis | Derives de nicotinamide,leur preparation et leur application en therapeutique |
| FR2943670B1 (fr) * | 2009-03-24 | 2011-05-06 | Sanofi Aventis | Derives anticancereux,leur preparation et leur application en therapeutique |
| FR2943675A1 (fr) * | 2009-03-24 | 2010-10-01 | Sanofi Aventis | Composes anticancereux, leur preparation et leur application en therapeutique |
| JP2012529535A (ja) * | 2009-06-12 | 2012-11-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼモジュレーターとして有用なニコチンアミド化合物 |
| US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
| CN103819393A (zh) * | 2010-03-01 | 2014-05-28 | 瑞科西有限公司 | 化合物及其治疗应用 |
| DK3150198T3 (da) | 2010-04-07 | 2021-11-01 | Vertex Pharma | Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf |
| US8827372B2 (en) | 2010-07-07 | 2014-09-09 | Frontis Corp. | Blowing system |
| FR2965263A1 (fr) * | 2010-09-24 | 2012-03-30 | Sanofi Aventis | Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique |
| US9169246B2 (en) | 2011-09-26 | 2015-10-27 | Sanofi | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof |
| ES2527188T3 (es) * | 2011-09-26 | 2015-01-21 | Sanofi | Derivados de pirazolquinolinona, su preparación y su uso terapéutico |
| CN103012397B (zh) * | 2011-09-26 | 2017-03-01 | 赛诺菲 | 吡唑并喹啉酮衍生物、其制备方法及其治疗用途 |
| US10231932B2 (en) | 2013-11-12 | 2019-03-19 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases |
| CN103804270B (zh) * | 2014-01-23 | 2016-06-22 | 中国药科大学 | 5-(4-甲脒基苄氧基)色氨酸衍生物、其制法及应用 |
| JP6494757B2 (ja) | 2014-11-18 | 2019-04-03 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ハイスループット試験高速液体クロマトグラフィーを行うプロセス |
| WO2017219935A1 (zh) | 2016-06-22 | 2017-12-28 | 复旦大学 | 联芳基脲类衍生物或其盐及其制备方法和用途 |
| CN107522641B (zh) * | 2016-06-22 | 2020-05-05 | 复旦大学 | 联芳基脲类衍生物或其盐及其制备方法和用途 |
| WO2019213570A1 (en) * | 2018-05-04 | 2019-11-07 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| CN110396065A (zh) * | 2019-06-25 | 2019-11-01 | 南京普锐达医药科技有限公司 | 一种2,4-二氯-5-嘧啶甲酰氯的合成方法 |
| CN114929672A (zh) * | 2019-11-06 | 2022-08-19 | 治疗方案股份有限公司 | 靶向癌症干细胞的癌症治疗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4301110A1 (de) * | 1993-01-18 | 1994-07-21 | Bayer Ag | Verfahren zur Herstellung von 2-Amino-5-aminomethyl-pyridin |
| ES2249059T3 (es) * | 1998-12-16 | 2006-03-16 | Bayer Healthcare Ag | Nuevos compuestos de bifenilo y analogos de bifenilo como antagonista de integrina. |
| DE10063008A1 (de) * | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
| US20040067985A1 (en) * | 2002-10-04 | 2004-04-08 | Fortuna Haviv | Method of inhibiting angiogenesis |
| EP1689376A2 (en) * | 2003-11-28 | 2006-08-16 | Novartis AG | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
| US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
-
2007
- 2007-09-28 FR FR0706799A patent/FR2921657A1/fr not_active Withdrawn
-
2008
- 2008-09-24 TW TW097136703A patent/TW200918056A/zh unknown
- 2008-09-26 AR ARP080104193A patent/AR066171A1/es unknown
- 2008-09-26 KR KR1020107006595A patent/KR20100065165A/ko not_active Application Discontinuation
- 2008-09-26 BR BRPI0817973-5A patent/BRPI0817973A2/pt not_active IP Right Cessation
- 2008-09-26 MX MX2010003445A patent/MX2010003445A/es not_active Application Discontinuation
- 2008-09-26 CL CL2008002893A patent/CL2008002893A1/es unknown
- 2008-09-26 UY UY31367A patent/UY31367A1/es not_active Application Discontinuation
- 2008-09-26 WO PCT/FR2008/001338 patent/WO2009074749A2/fr active Application Filing
- 2008-09-26 AU AU2008334457A patent/AU2008334457A1/en not_active Abandoned
- 2008-09-26 CN CN200880109332A patent/CN101808996A/zh active Pending
- 2008-09-26 JP JP2010526335A patent/JP2010540504A/ja not_active Withdrawn
- 2008-09-26 PE PE2008001687A patent/PE20091033A1/es not_active Application Discontinuation
- 2008-09-26 EP EP08859496A patent/EP2205566A2/fr not_active Withdrawn
- 2008-09-26 PA PA20088797301A patent/PA8797301A1/es unknown
- 2008-09-26 RU RU2010116765/04A patent/RU2010116765A/ru not_active Application Discontinuation
- 2008-09-26 CA CA2700559A patent/CA2700559A1/fr not_active Abandoned
-
2010
- 2010-03-22 IL IL204663A patent/IL204663A0/en unknown
- 2010-03-26 US US12/732,749 patent/US20100222319A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2010116765A (ru) | 2011-11-27 |
| CL2008002893A1 (es) | 2009-10-16 |
| WO2009074749A2 (fr) | 2009-06-18 |
| CN101808996A (zh) | 2010-08-18 |
| AU2008334457A1 (en) | 2009-06-18 |
| BRPI0817973A2 (pt) | 2019-04-09 |
| WO2009074749A3 (fr) | 2009-08-20 |
| PA8797301A1 (es) | 2009-05-15 |
| CA2700559A1 (fr) | 2009-06-18 |
| JP2010540504A (ja) | 2010-12-24 |
| EP2205566A2 (fr) | 2010-07-14 |
| UY31367A1 (es) | 2009-04-30 |
| MX2010003445A (es) | 2010-04-27 |
| FR2921657A1 (fr) | 2009-04-03 |
| PE20091033A1 (es) | 2009-08-17 |
| IL204663A0 (en) | 2010-11-30 |
| TW200918056A (en) | 2009-05-01 |
| KR20100065165A (ko) | 2010-06-15 |
| US20100222319A1 (en) | 2010-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066171A1 (es) | Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer. | |
| AR075920A1 (es) | Derivados de nicotinamida su preparacion y su aplicacion en terapeutica | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR083903A1 (es) | Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR084220A1 (es) | Acidos 1-bencilcicloalquilcarboxilicos sustituidos, su uso y metodo de preparacion | |
| AR097008A1 (es) | Derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CO6290657A2 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR083180A1 (es) | Amidas de oxopiperazina-azetidina y amidas oxodiazepina-azetidina como inhibidores de monoacilglicerol lipasa | |
| ECSP099269A (es) | Compuestos de fenilurea como inhibidores de epóxido hidrolasa soluble | |
| CO6300865A2 (es) | Derivados polisustituidos de 2 aril-6-fenil-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica | |
| RS54183B1 (en) | PIRAZOLE DERIVATIVES | |
| CO6362007A2 (es) | Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparación y su aplicación en terapeútica | |
| AR065891A1 (es) | Derivados de piridina y pirimidina como antagonistas del mglur2 | |
| AR065249A1 (es) | Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales. | |
| AR099914A1 (es) | Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR066955A1 (es) | Derivados de 7- alquinil -1,8- naftiridonas, su preparacion y su aplicacion en terapeutica | |
| RS50527B (sr) | Derivati indanil-piperazina, proces njihove izrade i farmaceutske smeše koje ih sadrže | |
| AR066524A1 (es) | Azetidinas, composiciones farmaceuticas que las comprenden y uso como antagonistas de ep2 | |
| AR082912A1 (es) | Metodo para producir compuestos de piridazinona y un intermediario de sintesis | |
| AR071619A1 (es) | Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias y composiciones farmaceuticas que los contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |